MedTrace Logo

Study of RP-6306 With FOLFIRI in Advanced Solid Tumors

NCT05147350 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2025-12-05

Study results available
· View outcomes & findings →

Summary

The primary purpose of this study is to assess the safety and tolerability of RP-6306 with FOLFIRI in patients with eligible advanced solid tumors, determine the maximum tolerated dose (MTD), identify a recommended phase 2 dose (RP2D) and preferred schedule, and assess preliminary anti-tumor activity.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

RP-6306 (oral PKMYT1 inhibitor)

RP-6306 (Oral) in combination with FOLFIRI (IV)

Sponsors & Collaborators

  • Repare Therapeutics

    collaborator INDUSTRY

  • Debiopharm International SA

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-09
Primary Completion
2025-02-12
Completion
2025-02-12
FDA Drug
Yes

Countries

  • United States
  • Canada
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05147350 on ClinicalTrials.gov